Board meeting on Oct 29 to consider Q2 and H1 FY26-27 results

Results View source PDF Explain this filing

ALIVUS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.7%Reaction day

₹1261.60

prior close

₹1259.90

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.0%+1.8% vs market

Pharmaceuticals peers, median of 170sector-0.5%+1.3% vs sector

On the reaction day the stock moved 1.8 pts more than Nifty Microcap 250 and 1.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-1.0

15m

-0.8

30m

-0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.7-1.0+1.8-0.5+1.3

Next day

-1.5-3.3+1.8-2.2+0.8

-0.1-2.9+2.8-1.1+1.0

+7.6pendingpending+0.7+7.0

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Alivus Life Sciences (formerly Glenmark Life Sciences) has informed the exchanges that its Board of Directors will meet on Thursday, October 29, 2026 to consider and approve the Unaudited Financial Results for the quarter and half year ended September 30, 2026. The trading window for designated persons is closed from October 1 to October 31, 2026 in line with insider trading rules.

Likely market impact

Routine intimation with no numbers yet. Investors should watch for the Q2 and H1 results on October 29 for actual earnings performance.